Tilak Gains CE Marking for Odysight, a Mobile Medical Game for Chronic Eye Disease

June 29, 2018: By Jon Swedien

Tilak has gained CE marking for Odysight, the company’s mobile medical game for monitoring patients with chronic eye disease, the Paris-based firm announced June 14.

The puzzle game for smartphones and tablets monitors the evolution of visual parameters—near visual acuity, contrast sensitivity, and the presence and evolution of scotomas or metamorphosis—and triggers regular medical tests for patient follow-up.

In-house doctors and video game professionals worked together to create the game, which includes elements of a modern mobile video game—artistic direction, simple game mechanics, and a level of difficulty adapted to the patient.

Odysight is available on Apple’s App Store and the Google Play store by medical prescription.

Tilak was founded in May 2016 and is part of the iBionext network. iBionext has helped create eight companies, including Pixium Vision and GenSight Biologics, the management company said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility